Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Abstract

In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).

Keywords

Affiliated Institutions

• UCSF Helen Diller Family Comprehensive Cancer Center US
• St. Vincent's Hospital KR
• Royal Prince Alfred Hospital AU
• The University of Melbourne AU
• Emory University US
• University Hospital Cologne DE
• The University of Texas MD Anderson Cancer Center US
• University of Pennsylvania US
• Hospices Civils de Lyon FR
• Université Claude Bernard Lyon 1 FR
• Karolinska Institutet SE
• Michigan Center for Translational Pathology US
• UPMC Hillman Cancer Center US
• Peter MacCallum Cancer Centre AU
• University Medical Center US
• St Vincent's Hospital Melbourne AU
• Oslo University Hospital
• Juravinski Hospital CA
• University of Chicago US
• The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute US
• Novartis Institutes for BioMedical Research
• Medical University of Vienna AT
• University of Minnesota US
• Novartis (Switzerland) CH
• The University of Kansas Cancer Center US
• Hôpital Maisonneuve-Rosemont CA
• University of Michigan US
• Université de Montréal CA
• McMaster University CA
• The University of Sydney AU
• Oregon Health & Science University US
• University of California, San Francisco US
• Novartis (France) FR

Related Publications